RINGTX Trademark

Trademark Overview


On Wednesday, January 29, 2025, a trademark application was filed for RINGTX with the United States Patent and Trademark Office. The USPTO has given the RINGTX trademark a serial number of 99022541. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, August 7, 2025. This trademark is owned by Ring Therapeutics, Inc.. The RINGTX trademark is filed in the Pharmaceutical Products and Treatment & Processing of Materials Services categories with the following description:

Custom manufacture of anelloviruses

Encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of human diseases and disorders; pharmaceutical preparations for use in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases
ringtx

General Information


Serial Number99022541
Word MarkRINGTX
Filing DateWednesday, January 29, 2025
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateThursday, August 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, August 26, 2025

Trademark Statements


Goods and ServicesCustom manufacture of anelloviruses
Description of MarkThe mark consists of the stylized wording RINGTX.
Goods and ServicesEncapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of human diseases and disorders; pharmaceutical preparations for use in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases
Pseudo MarkRING TX

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 29, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateWednesday, January 29, 2025
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRing Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141

Trademark Events


Event DateEvent Description
Wednesday, January 29, 2025APPLICATION FILING RECEIPT MAILED
Monday, June 30, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 9, 2025ASSIGNED TO EXAMINER
Thursday, July 10, 2025NON-FINAL ACTION WRITTEN
Thursday, July 10, 2025NON-FINAL ACTION E-MAILED
Thursday, July 10, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 24, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 24, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 24, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 25, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 29, 2025NEW APPLICATION ENTERED